Is semaglutide legal in the United States? Yes, as a prescription medicine. FDA has approved it as Ozempic, Rybelsus and Wegovy, in injection and tablet forms. The harder questions are about salt forms, compounding after the shortage ended, and semaglutide sold outside the prescription system. This guide takes them one at a time, using Drugs@FDA, DailyMed, FDA orders and warning letters checked on November 17, 2026.
Quick answer: Semaglutide is legal to prescribe and dispense as Ozempic, Rybelsus or Wegovy. Compounding is now limited. A 503A pharmacy may not regularly compound copies of the approved products, and semaglutide is on neither the 503B bulks list nor FDA’s shortage list. FDA treats semaglutide sold for human use outside an approved application as an unapproved new drug, and a “research use only” label has not changed that when marketing showed human use. Research-grade semaglutide is a laboratory reagent, not an alternative to a prescription medicine.
This article summarizes public regulatory records. It is not legal advice. For a decision about your own situation, ask a lawyer.
Is semaglutide FDA-approved?
Yes. Drugs@FDA lists these Novo Nordisk applications, each with marketing status “Prescription”:
- Ozempic injection, NDA 209637, approved December 5, 2017 as a new molecular entity (Drugs@FDA);
- Rybelsus tablets, NDA 213051, approved September 20, 2019; the same application now also lists Ozempic tablets (Drugs@FDA);
- Wegovy injection, NDA 215256, approved June 4, 2021 (Drugs@FDA); and
- Wegovy tablets, NDA 218316, whose first label is dated December 2025 (FDA label).
The current labels on DailyMed set out the approved uses. Ozempic injection (revised May 2026) is indicated to improve glycemic control in adults with type 2 diabetes, to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (DailyMed). Rybelsus and Ozempic tablets (revised January 2026) cover glycemic control and cardiovascular risk reduction in adults with type 2 diabetes (DailyMed). Wegovy (revised June 2026) is indicated, with diet and increased physical activity, for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, and for weight reduction. The injection also has an accelerated approval for a form of liver disease called MASH with moderate to advanced fibrosis (DailyMed). For what the labels contain, see semaglutide and tirzepatide prescription labels. For costs, see semaglutide price.
What about semaglutide sodium and semaglutide acetate?
The approved drugs contain semaglutide base. FDA states that some compounders may sell salt forms, and that “these salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients” from the ones in approved drugs. FDA says it is “not aware of any lawful basis for their use in compounding” (FDA, 2026). In an October 2023 warning letter, FDA wrote that products containing these salts “have not been shown to be safe and effective” (FDA, 2023).
Can semaglutide still be compounded?
Only within narrow limits. Semaglutide injection products were added to FDA’s shortage list in March 2022 for Wegovy and August 2022 for Ozempic. In a declaratory order dated February 21, 2025, FDA “determined that the semaglutide injection product shortage is resolved” (FDA, 2025). After a court denied a preliminary injunction on April 24, 2025, FDA said the 503A wind-down period had ended; the 503B period ran to May 22, 2025 (FDA, 2026). On August 27, 2026, the Fifth Circuit affirmed the district court’s judgment in the compounders’ challenge (No. 25-10758).
FDA’s current policy, updated April 1, 2026, sets out what remains. A 503A pharmacy must compound for an individual patient on a prescription and may not compound essentially copies of a commercially available product “regularly or in inordinate amounts”; FDA does not intend to act on four or fewer such prescriptions in a calendar month. For 503B facilities, FDA wrote: “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.” On April 30, 2026, FDA proposed not to include semaglutide on that list, finding “no clinical need” (FDA, 2026). Comments closed on July 30, 2026, and we found no final decision. Compounded drugs are not FDA-approved. See compounded semaglutide and the FDA and 503A vs 503B compounding.
Has FDA warned sellers of unapproved semaglutide?
Yes, many times. FDA says it has warned companies that sold unapproved semaglutide and similar products “falsely labeled” for research purposes or not for human consumption. Table 1 shows the letters and status checks we read.
Semaglutide: approvals, FDA actions and status checks
| Date | What happened |
|---|---|
| December 5, 2017 | FDA approves Ozempic injection (NDA 209637) |
| September 20, 2019 | FDA approves Rybelsus tablets (NDA 213051) |
| June 4, 2021 | FDA approves Wegovy injection (NDA 215256) |
| April 24, 2024 | Warning letter to an online seller of unapproved, misbranded oral semaglutide products |
| December 10, 2024 | Warning letter to a seller of semaglutide labeled “research use only” |
| February 21, 2025 | FDA order: semaglutide injection shortage resolved |
| May 22, 2025 | Last day of FDA’s 503B wind-down period |
| September 9, 2025 | Warning letter over compounded semaglutide marketed as having the “same active ingredient” as Ozempic and Wegovy |
| March 3, 2026 | FDA announces 30 warning letters to telehealth companies over compounded GLP-1 marketing |
| April 30, 2026 | FDA proposes not to include semaglutide on the 503B bulks list |
| August 24, 2026 | Warning letters to two sellers of research-labeled semaglutide |
| November 12, 2026 | DEA controlled substances list edition; semaglutide not listed |
The research-labeled cases follow one pattern. The December 2024 letter quoted “RESEARCH USE ONLY.” The February 2025 letter quoted “research use only” and “not for human consumption.” The August 2026 letters to Peptide Partners LLC and Tex Peptides quoted “not for human or veterinary use.” Each time, FDA wrote that evidence from the seller’s website established that the products were intended to be drugs for human use, and cited sections 505(a) and 301(d) of the Act. Our guide to FDA warning letters to peptide sellers lists each letter.
FDA also writes to online pharmacy websites that make no research claim at all. On September 23, 2026, it sent a warning letter to Online Generic Medicine/www.onlinegenericmedicine.com. On September 24, 2026, it sent one to Cheap Medicine Shop/www.cheapmedicineshop.com. FDA said it reviewed each website on August 26 and September 2, 2026, and that each introduced unapproved and misbranded injectable semaglutide products into interstate commerce. Each letter states that no approved application is in effect for the product it names, and cites sections 505(a), 301(d), 301(a), 502(f)(1) and 503(b)(1) of the Act. Both letters note that FDA-approved semaglutide products are available only by prescription. A warning letter states FDA’s view. It is not a court finding.
Is semaglutide a controlled substance?
Not under federal law. Semaglutide does not appear on the DEA’s alphabetical list of controlled substances, edition dated November 12, 2026 (DEA). That does not make a product lawful to sell as a drug. That question belongs to FDA.
What does research-use-only sale mean, and what are its limits?
A “research use only” label states the seller’s intended use: laboratory research, not use in people or animals. Research-grade semaglutide is a laboratory reagent. It is not Ozempic, Rybelsus or Wegovy, it is not made under an approved application, and it is not a substitute for a prescription medicine.
The label does not decide the legal question by itself. FDA judges intended use by “objective intent,” which may be shown by a seller’s expressions or “the circumstances surrounding the distribution of the article” (21 CFR 201.128). When the evidence shows a product is meant for people, FDA can treat it as an unapproved new drug despite the label.
Research-grade semaglutide in our catalog is sold for laboratory research use only, not for human or veterinary use. See also what research use only means.
Frequently asked questions about semaglutide legality
Is semaglutide FDA-approved?
Yes, as Ozempic, Rybelsus and Wegovy, in injection and tablet forms. All are prescription-only.
Can a pharmacy still compound semaglutide?
Only within limits. A 503A pharmacy may not regularly compound copies of the approved products. Semaglutide is on neither the 503B bulks list nor FDA’s shortage list.
Are semaglutide sodium and semaglutide acetate the same as semaglutide?
No. FDA says these salt forms are different active ingredients from the base form in the approved drugs, and it knows of no lawful basis for using them in compounding.
Does a “research use only” label make semaglutide legal to sell?
Not by itself. When website evidence showed human use, FDA treated research-labeled semaglutide as an unapproved new drug.
Is semaglutide a controlled substance?
No. It is not on the DEA’s federal list.
What to know now
- FDA approval: Ozempic, Rybelsus and Wegovy, prescription only.
- Salt forms: FDA says semaglutide sodium and acetate are different active ingredients.
- Shortage: resolved February 21, 2025; wind-down periods ended by May 22, 2025.
- 503B: not on the bulks list or the shortage list; FDA proposed leaving it off the list.
- Enforcement: warning letters through August 2026 looked past research-use labels.
- Research grade: for laboratory research use only, not for human or veterinary use.
What we’re watching
FDA’s final decision on its proposal to leave semaglutide off the 503B bulks list. New FDA warning letters to sellers of research-labeled or salt-form semaglutide. And further label changes for Ozempic, Rybelsus and Wegovy listed on Drugs@FDA.